As the sole public company developing therapies for spinal cord injury treatment with exosomes, NurExone is proud to broaden its financial market access. The OTCQB, a renowned U.S. trading platform, is a pivotal gateway to US trading, fostering an environment conducive to informed investment decisions. This enhances opportunities to attract

Dr. Shaltiel joins a prestigious lineup of speakers presenting applications of exosomes, including representatives from leading exosome companies such as Abbvie, Evox Therapeutics and Capricor Therapeutics, as well as senior-level executives in the field. As a pioneer and leader in this field, Dr. Shaltiel is well-positioned to provide perspective on